Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed

Rossig, Claudia; Pearson, Andrew D.; Vassal, Gilles; Scobie, Nicole; Bird, Nick; Blanc, Patricia; Vormoor, H. Josef; Calkoen, Friso G.; Locatelli, Franco; Bufalo, Francesca del; Rives, Susana; Jacoby, Elad; Balduzzi, Adriana; Bourquin, Jean-Pierre; Baruchel, André

doi:10.1200/jco.23.01314

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 7 publications

(1 citation statement)

References 49 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are several ongoing clinical trials focusing on new modes of treatment for this group of patients (https://clinicaltrials.gov/search?cond=neuroblastoma%20relapse, access on 2 February 2024). Furthermore, recent detailed mapping of the immune cell landscape of neuroblastoma and novel immunotherapy approaches, including GD2-CAR-T and ALK-CAR-T, have indicated that there are new approaches to treating and potentially curing patients with refractory or relapsed neuroblastoma on the horizon [20][21][22][23].…”

mentioning

confidence: 99%